MAPK9 and diabetic kidney disease: A synthetic curcumin analogue (C66), targeting JNK2, could decrease HG-induced inflammatory injury both in vitro and in vivo via the mechanism involving NF-κB and macrophage infiltration, indicating that C66 is a potential candidate for the treatment of diabetic nephropathy.